Stay updated on ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial
Sign up to get notified when there's something new on the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page.
![Latest website image capture](/pages/_next/image?url=https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fvp-files-ore%2Fresources%2F12months%2F_GJD-0T9fZUu-ZPWI-8ilCibkMY.uncropped.jpg&w=3840&q=75)
Latest updates to the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page
- ChecktodayNo Change Detected
- Check2 days agoNo Change Detected
- Check3 days agoNo Change Detected
- Check4 days agoChange DetectedThe study has been updated to version v2.10.0, with two locations now included, replacing the previous version v2.9.7.SummaryDifference0.5%
- Check5 days agoNo Change Detected
- Check11 days agoChange DetectedThe website has been updated to Revision v2.9.7 from v2.9.6.SummaryDifference0.1%
- Check25 days agoChange DetectedThe value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check30 days agoChange DetectedThe value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check31 days agoChange DetectedThe value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the webpage.SummaryDifference0.1%
- Check32 days agoChange DetectedThe value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less Drug Information available for: Nivolumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : ABX196 IM injection of 0.1, 0.2, and 0.4 µg of ABX196 Drug : ABX196 ABX196 will be administered as an IM injection 120 minutes (+/- 15 minutes) after the completion of the nivolumab infusion on Day 1 of every other 28-Day treatment cycle (i.e., every 8 weeks).' This change represents an update in the drug information and study design details for the clinical trial involving ABX196 in combination with Nivolumab for patients with Hepatocellular Carcinoma.SummaryDifference19%
Stay in the know with updates to ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ABX196+Nivolumab in Hepatocellular Carcinoma Clinical Trial page.